[go: up one dir, main page]

PE20060461A1 - Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino - Google Patents

Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino

Info

Publication number
PE20060461A1
PE20060461A1 PE2005000682A PE2005000682A PE20060461A1 PE 20060461 A1 PE20060461 A1 PE 20060461A1 PE 2005000682 A PE2005000682 A PE 2005000682A PE 2005000682 A PE2005000682 A PE 2005000682A PE 20060461 A1 PE20060461 A1 PE 20060461A1
Authority
PE
Peru
Prior art keywords
combination
her2 antibody
gemcitabin
platinum
treatment
Prior art date
Application number
PE2005000682A
Other languages
English (en)
Inventor
Stephen M Kelsey
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060461(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20060461A1 publication Critical patent/PE20060461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMBINACION DE UN ANTICUERPO HER2 QUE INHIBE LA DIMERIZACION DEL HER Y UN AGENTE QUIMIOTERAPEUTICO DE ANTIMETABOLITOS. DE PREFERENCIA EL ANTICUERPO HER2 ES PERTUZUMAB Y EL COMPUESTO ANTIMETABOLITO ES GEMCITABINA. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO TAL COMO CANCER DE OVARIO, CARCINOMA PERITONEAL PRIMARIO O CARCINOMA DE TROMPAS DE FALOPIO
PE2005000682A 2004-06-16 2005-06-15 Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino PE20060461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58033304P 2004-06-16 2004-06-16

Publications (1)

Publication Number Publication Date
PE20060461A1 true PE20060461A1 (es) 2006-08-04

Family

ID=35432102

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000682A PE20060461A1 (es) 2004-06-16 2005-06-15 Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino

Country Status (27)

Country Link
US (2) US20060013819A1 (es)
EP (1) EP1755671B1 (es)
JP (3) JP2008503476A (es)
KR (3) KR20070029804A (es)
CN (2) CN105194667A (es)
AR (1) AR049305A1 (es)
AU (2) AU2005262459B2 (es)
BR (1) BRPI0511377A (es)
CA (1) CA2567808C (es)
DK (1) DK1755671T3 (es)
ES (1) ES2398689T3 (es)
GT (1) GT200500155A (es)
IL (1) IL179401A (es)
JO (1) JO2794B1 (es)
MX (1) MXPA06014687A (es)
MY (1) MY163024A (es)
NO (1) NO20070243L (es)
NZ (1) NZ551376A (es)
PA (1) PA8637101A1 (es)
PE (1) PE20060461A1 (es)
PL (1) PL1755671T3 (es)
RU (1) RU2403065C2 (es)
SI (1) SI1755671T1 (es)
SV (1) SV2006002143A (es)
TW (1) TWI375564B (es)
WO (1) WO2006007398A1 (es)
ZA (1) ZA200610132B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CN1447696A (zh) 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
TWI441646B (zh) * 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
MY152164A (en) * 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
CN101495142A (zh) * 2006-06-05 2009-07-29 健泰科生物技术公司 延长EGF或TGF-α水平升高的癌症患者的存活
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
SI2132573T1 (sl) * 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
JP2010006705A (ja) * 2008-06-13 2010-01-14 Atlas Antibodies Ab Ｈｅｒ２サブセット
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CN102753193A (zh) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
MX2011010169A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-1/anti-c-met.
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
WO2011038068A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes
EP3778917A3 (en) * 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
EP2513148B1 (en) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
KR20180028561A (ko) * 2010-02-23 2018-03-16 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
MX364637B (es) 2010-03-29 2019-05-03 Abraxis Bioscience Llc Star Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
CA2801645A1 (en) 2010-06-04 2011-12-08 Abraxis Bioscience, Llc Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20140161827A1 (en) * 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
ES2553456T3 (es) 2011-09-02 2015-12-09 Nestec S.A. Perfilado de proteínas de ruta de señal para determinar una eficacia terapéutica
KR102679155B1 (ko) 2011-10-14 2024-06-28 제넨테크, 인크. Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
JP6187960B2 (ja) * 2012-01-20 2017-08-30 日本製粉株式会社 がんの治療又は予防剤
AU2013231410B2 (en) * 2012-03-13 2017-08-17 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
MX354717B (es) * 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.
EP2638916A1 (en) * 2012-03-16 2013-09-18 Covagen AG Novel binding molecules with antitumoral activity
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
WO2014208760A1 (ja) * 2013-06-27 2014-12-31 国立大学法人九州大学 抗がんモノクローナル抗体及びその製造方法
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
WO2015164665A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
HRP20241134T1 (hr) 2015-05-30 2024-11-22 F. Hoffmann-La Roche Ag Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke
US9770462B2 (en) 2015-10-05 2017-09-26 National Cheng Kung University Method of treating ovarian, tubal and peritoneal cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
MX2019005144A (es) 2016-11-04 2019-10-14 Genentech Inc Tratamiento de cáncer de mama positivo para her2.
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
KR20200113292A (ko) 2017-01-17 2020-10-06 제넨테크, 인크. 피하 her2 항체 제형
SI3589661T1 (sl) 2017-03-02 2024-03-29 Genentech, Inc. Adjuvansno zdravljenje her2 pozitivnega raka dojke
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
RU2738167C1 (ru) * 2020-06-08 2020-12-09 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
WO1995014776A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
WO1995014930A1 (en) 1993-11-23 1995-06-01 Genentech, Inc. Kinase receptor activation assay
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
DK1308456T3 (da) * 1998-05-06 2007-12-27 Genentech Inc Antistofoprensning ved ionbytterkromatografi
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
NZ516830A (en) * 1999-06-25 2004-07-30 Genentech Inc Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CA2383493C (en) * 1999-06-25 2010-08-10 Genentech, Inc. Treating prostate cancer with anti-erbb2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
HU231064B1 (hu) * 1999-08-27 2020-03-30 Genentech, Inc. Anti-ErbB2 antitestek adagolási sémái és alkalmazásuk rákos betegségek kezelésére
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
JP2004002211A (ja) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd 癌の予防・治療方法
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
GB0215593D0 (en) * 2002-07-05 2002-08-14 Univ Leeds New anticancer drugs
NZ537660A (en) * 2002-07-15 2008-12-24 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
AU2003295798B2 (en) * 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
AU2005232657B2 (en) * 2004-04-08 2010-12-16 David B. Agus ErbB antagonists for pain therapy
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
EP1755608A1 (en) * 2004-06-03 2007-02-28 F.Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
TWI441646B (zh) * 2005-01-21 2014-06-21 Genentech Inc 帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
MY152164A (en) * 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US9135948B2 (en) 2009-07-03 2015-09-15 Microsoft Technology Licensing, Llc Optical medium with added descriptor to reduce counterfeiting

Also Published As

Publication number Publication date
IL179401A (en) 2012-12-31
JP2013014611A (ja) 2013-01-24
PL1755671T3 (pl) 2013-05-31
GT200500155A (es) 2006-05-15
DK1755671T3 (da) 2013-03-25
EP1755671A1 (en) 2007-02-28
AU2005262459B2 (en) 2010-12-09
SI1755671T1 (sl) 2013-03-29
JO2794B1 (en) 2014-03-15
NO20070243L (no) 2007-01-15
CA2567808C (en) 2014-03-18
CN101014366A (zh) 2007-08-08
MXPA06014687A (es) 2007-02-12
US20060013819A1 (en) 2006-01-19
IL179401A0 (en) 2007-05-15
KR20070029804A (ko) 2007-03-14
JP2015157831A (ja) 2015-09-03
RU2403065C2 (ru) 2010-11-10
KR20140012197A (ko) 2014-01-29
EP1755671B1 (en) 2012-12-12
KR20130038407A (ko) 2013-04-17
WO2006007398A1 (en) 2006-01-19
TW200610538A (en) 2006-04-01
RU2007101378A (ru) 2008-07-27
JP2008503476A (ja) 2008-02-07
US20120107391A1 (en) 2012-05-03
BRPI0511377A (pt) 2007-12-04
AR049305A1 (es) 2006-07-12
AU2011200947A1 (en) 2011-03-24
CN105194667A (zh) 2015-12-30
MY163024A (en) 2017-07-31
NZ551376A (en) 2009-11-27
KR101517715B1 (ko) 2015-05-04
TWI375564B (en) 2012-11-01
ZA200610132B (en) 2009-08-26
HK1102757A1 (en) 2007-12-07
ES2398689T3 (es) 2013-03-21
PA8637101A1 (es) 2006-05-16
AU2005262459A1 (en) 2006-01-19
SV2006002143A (es) 2006-01-26
CA2567808A1 (en) 2006-01-19
WO2006007398A9 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
PE20060461A1 (es) Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino
MX2009008981A (es) Prediccion de respuesta a un inhibidor her.
MX2020001550A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
PE20142046A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
PE20121555A1 (es) COMBINACION DE UN AGENTE INDUCTOR DE POLIPLOIDIA Y UN INHIBIDOR Bcl-2
CL2009000721A1 (es) Combinacion que comprende un anticuerpo aislado anti-igf1r o un fragmento de fijacion de antigeno del mismo en asociacion con leucovorina y 5-fluorouracilo, leucovorina o sunitinib opcionalmente asociado con otro agente quimioterapeutico; y su uso para el tratamiento o prevencion del cancer colorectal.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
PE20170242A1 (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
PA8850801A1 (es) Compuestos útiles para inhibir chk1
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CL2011001256A1 (es) Combinacion farmaceutica que comprende a un anticuerpo que reconoce especificamente a cd38, y ciclofosfamida, donde dicho anticuerpo es capaz de eliminar una celula cd38+ por apoptosis, citotoxicidad mediada por celulas dependiente de anticuerpo (adcc), y citotoxicidad dependiente de complemento (cdc).
PE20090975A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma
MX2019001315A (es) Tratamiento conjunto contra tipos de cancer hematologico.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
PE20081553A1 (es) Composicion farmaceutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.

Legal Events

Date Code Title Description
FC Refusal